New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.52
0.37
−0.95%
Follow NVO
Alert me
What it owns vs. what it owes Q3 FY2026, Sep 30, 2026
It owes $13.2B more in debt than it holds in cash and short-term investments. Shareholders’ equity is 36.4% of the balance sheet. What is a balance sheet?
Owns
$59.8BLong-term assets
$24.9BOther short-term assets
$7.5BCash & short-term investments
Funded by
$33.5BShareholders’ equity
$38.0BOther liabilities
$20.7BDebt
Debt is 22.4% of the total; shareholders’ equity 36.4%.
Net debt has held near 14% of assets since Q4 FY25.
Net debt ÷ assets (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Total assets | $82.2B | $87.6B | $92.6B | $92.3B |
| Net debt (debt less cash) | $14.7B | $18.9B | $14.2B | $13.2B |
| Net debt ÷ assets (right axis) | 17.9% | 21.6% | 15.3% | 14.3% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
5,093.70 | 4,024.15 | 7,598.26 | 7,539.38 |
Receivables |
13,502.76 | 15,701.97 | 16,884.47 | 17,033.32 | |
Inventory |
7,512.92 | 8,041.72 | 7,990.37 | 7,885.57 | |
Total current assets |
26,109.38 | 27,767.84 | 32,473.10 | 32,458.27 | |
Property, Plant, Equpment (Net) |
31,548.43 | 34,447.93 | 36,061.54 | 37,081.20 | |
Long-Term Investments |
379.56 | 350.94 | 362.55 | 385.15 | |
Long-term receivables |
887.81 | 938.35 | 1,000.20 | 993.30 | |
Goodwill and Intangible Assets (Total) |
19,690.02 | 20,343.91 | 18,992.07 | 17,213.04 | |
Long Term Assets (Tax, Deferred) |
3,580.16 | 3,725.04 | 3,683.36 | 4,139.67 | |
Total non-current assets |
56,085.98 | 59,806.17 | 60,099.72 | 59,812.37 | |
Total Assets |
82,195.36 | 87,574.01 | 92,572.82 | 92,270.64 | |
Accounts Payable |
2,991.36 | 2,318.15 | 2,270.36 | 2,343.42 | |
Current Part of Debt |
1,819.37 | 4,261.09 | 2,852.62 | 2,577.65 | |
Current Part of Taxes to Pay |
1,274.18 | 2,528.93 | 3,183.58 | 4,248.24 | |
Other current liabilities |
26,566.16 | 26,151.57 | 28,894.76 | 29,245.99 | |
Total current liabilities |
32,651.08 | 35,259.74 | 37,201.32 | 38,415.30 | |
Long Term Debt (Total) |
18,007.67 | 18,662.34 | 18,951.15 | 18,132.27 | |
Pension and Post-Retirement Liabilities |
130.36 | 129.04 | 122.46 | 102.41 | |
Long Term Tax Liability (Deferred) |
1,000.91 | 784.25 | 664.57 | 551.78 | |
Non-current Liabilities (Other) |
1,026.64 | 938.66 | 1,202.63 | 1,527.37 | |
Total non-current liabilities |
20,165.57 | 20,514.29 | 20,940.80 | 20,313.83 | |
Total liabilities |
52,816.65 | 55,774.03 | 58,142.12 | 58,729.13 | |
Common Stock (Net) |
67.52 | 69.84 | 69.40 | 68.68 | |
Retained Earnings |
29,568.12 | 32,325.37 | 34,879.92 | 33,965.01 | |
Treasury Stock |
0.30 | 0.31 | 0.62 | 0.92 | |
Shareholders Equity (Other) |
(256.62) | (594.92) | (517.99) | (491.26) | |
Common Equity (Total) |
29,378.71 | 31,799.98 | 34,430.70 | 33,541.50 | |
Shareholders Equity (Total) |
29,378.71 | 31,799.98 | 34,430.70 | 33,541.51 | |
Shareholders Equity and Liabilities (Total) |
82,195.36 | 87,574.01 | 92,572.82 | 92,270.64 | |
Shares (Common) |
4,465.00 | — | — | — | |
Shareholders Equity (Tangible) |
9,688.69 | 11,456.07 | 15,438.63 | 16,328.47 | |
Net Debt |
14,733.34 | 18,899.28 | 14,205.51 | 13,170.54 | |
Total Debt |
19,827.04 | 22,923.43 | 21,803.77 | 20,709.92 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026